Previous 10 | Next 10 |
Iterum Therapeutics (ITRM) announces that the U.S. FDA has determined that an advisory committee meeting is not currently necessary for the company's new drug application ((NDA)) for its urinary tract infections treatment sulopenem.Shares up more than 11% post ma...
DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathog...
Penny Stocks To Buy According To Top Wall Street Firms What do you look for when it comes to finding penny stocks to buy? Are you hunting for momentum? Should corporate filings be part of your research? Will news headlines play a role in your decision-making? What about industry sentime...
Iterum Therapeutics plc (ITRM) Q1 2021 Earnings Conference Call May 14, 2021 08:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Gregory Renza - RB...
Shares of Iterum Therapeutics (ITRM) are up more than 7% in morning trading despite missing Q1 EPS estimates.The company's net loss widened significantly to $98.9M from $16.1M in the year-ago period.Q1 GAAP EPS of -$0.81 missed by $0.75.The company had no revenue.Iterum says its exi...
Iterum Therapeutics (ITRM): Q1 GAAP EPS of -$0.81 misses by $0.75.Cash, cash equivalents and short-term investments of $100.5 million as of March 31, 2021 allows us to operate into the first half of 2023.Press Release For further details see: Iterum Therapeutics EPS misses by $0.75
FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at 8:30am ET DUBLIN, Ireland and CHICAGO, May 14, 2021 (GLOBE NEWSWIRE...
DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both comm...
Iterum Therapeutics plc is a small late-clinical-stage pharmaceutical company developing Sulopenem, their lead and sole therapeutic for urinary tract and intra-abdominal infections. Iterum has tested their sole candidate Sulopenem in 3 simultaneous Phase 3 trials, but none met their p...
Iterum is developing sulopenem for uncomplicated urinary tract infections. The molecule was licensed from Pfizer. It hasn't done too well in trials. For further details see: Iterum: Failed Trials, Delayed NDAs, And Dilutions
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
Iterum Therapeutics plc Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...